Concepts (173)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Non-alcoholic Fatty Liver Disease | 17 | 2024 | 422 | 5.420 |
Why?
|
| Liver Cirrhosis | 11 | 2024 | 929 | 1.530 |
Why?
|
| Elasticity Imaging Techniques | 5 | 2024 | 138 | 1.250 |
Why?
|
| Fatty Liver | 3 | 2025 | 205 | 1.140 |
Why?
|
| Hepatitis C, Chronic | 2 | 2019 | 373 | 0.860 |
Why?
|
| Liver | 6 | 2025 | 1842 | 0.850 |
Why?
|
| Liver Diseases | 3 | 2023 | 385 | 0.830 |
Why?
|
| Stomach Neoplasms | 2 | 2018 | 561 | 0.740 |
Why?
|
| Portal System | 1 | 2021 | 34 | 0.720 |
Why?
|
| Collateral Circulation | 1 | 2021 | 44 | 0.700 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2021 | 41 | 0.680 |
Why?
|
| Point-of-Care Testing | 1 | 2020 | 31 | 0.670 |
Why?
|
| Patient Safety | 1 | 2024 | 426 | 0.640 |
Why?
|
| Duty to Warn | 1 | 2019 | 2 | 0.630 |
Why?
|
| Professional Impairment | 1 | 2019 | 3 | 0.630 |
Why?
|
| Alcoholic Intoxication | 1 | 2019 | 11 | 0.620 |
Why?
|
| Confidentiality | 1 | 2019 | 106 | 0.580 |
Why?
|
| Neonatal Abstinence Syndrome | 1 | 2018 | 20 | 0.580 |
Why?
|
| Feeding Behavior | 1 | 2023 | 726 | 0.560 |
Why?
|
| Community Health Services | 1 | 2018 | 92 | 0.550 |
Why?
|
| Electric Impedance | 1 | 2017 | 67 | 0.540 |
Why?
|
| Global Health | 2 | 2023 | 608 | 0.540 |
Why?
|
| Anthropometry | 1 | 2017 | 202 | 0.520 |
Why?
|
| Continuity of Patient Care | 1 | 2018 | 153 | 0.520 |
Why?
|
| Alcoholism | 1 | 2019 | 247 | 0.520 |
Why?
|
| Patient Compliance | 1 | 2019 | 480 | 0.510 |
Why?
|
| Acculturation | 1 | 2016 | 69 | 0.510 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2016 | 82 | 0.500 |
Why?
|
| Mouth Neoplasms | 1 | 2017 | 114 | 0.500 |
Why?
|
| Arteriolosclerosis | 1 | 2015 | 2 | 0.490 |
Why?
|
| Cross-Sectional Studies | 8 | 2023 | 3681 | 0.490 |
Why?
|
| Bile Duct Neoplasms | 1 | 2017 | 120 | 0.490 |
Why?
|
| Spleen | 1 | 2016 | 291 | 0.490 |
Why?
|
| Mexican Americans | 1 | 2016 | 207 | 0.470 |
Why?
|
| Severity of Illness Index | 1 | 2023 | 3032 | 0.470 |
Why?
|
| Diabetic Angiopathies | 1 | 2015 | 72 | 0.460 |
Why?
|
| Humans | 36 | 2025 | 132393 | 0.460 |
Why?
|
| Middle Aged | 16 | 2025 | 28944 | 0.450 |
Why?
|
| Adult | 15 | 2025 | 31578 | 0.450 |
Why?
|
| Carcinoma | 1 | 2017 | 321 | 0.450 |
Why?
|
| Adipose Tissue | 1 | 2017 | 499 | 0.440 |
Why?
|
| Thyroid Neoplasms | 1 | 2017 | 256 | 0.440 |
Why?
|
| Internship and Residency | 1 | 2024 | 1234 | 0.430 |
Why?
|
| Risk Factors | 10 | 2024 | 10923 | 0.420 |
Why?
|
| Mass Screening | 1 | 2019 | 828 | 0.420 |
Why?
|
| Exercise | 4 | 2023 | 874 | 0.410 |
Why?
|
| Prevalence | 6 | 2022 | 2631 | 0.410 |
Why?
|
| Obesity | 5 | 2024 | 2395 | 0.400 |
Why?
|
| Prebiotics | 1 | 2012 | 29 | 0.400 |
Why?
|
| Kidney Neoplasms | 1 | 2017 | 459 | 0.390 |
Why?
|
| Metagenome | 1 | 2012 | 158 | 0.370 |
Why?
|
| Nutrition Surveys | 5 | 2022 | 307 | 0.360 |
Why?
|
| Male | 17 | 2024 | 64985 | 0.350 |
Why?
|
| Pancreatic Neoplasms | 1 | 2017 | 731 | 0.350 |
Why?
|
| Female | 19 | 2025 | 70660 | 0.350 |
Why?
|
| Life Style | 3 | 2022 | 452 | 0.340 |
Why?
|
| Probiotics | 1 | 2012 | 229 | 0.320 |
Why?
|
| Alcohol Drinking | 2 | 2023 | 386 | 0.300 |
Why?
|
| Weight Loss | 2 | 2023 | 513 | 0.300 |
Why?
|
| Intestines | 1 | 2012 | 610 | 0.300 |
Why?
|
| Helicobacter pylori | 1 | 2017 | 1330 | 0.280 |
Why?
|
| Helicobacter Infections | 1 | 2017 | 1273 | 0.280 |
Why?
|
| Hypertension | 2 | 2021 | 1382 | 0.280 |
Why?
|
| United States | 7 | 2022 | 11465 | 0.280 |
Why?
|
| Biomarkers | 4 | 2021 | 3373 | 0.270 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2015 | 837 | 0.270 |
Why?
|
| Diet | 3 | 2023 | 1192 | 0.270 |
Why?
|
| Aspartate Aminotransferases | 2 | 2016 | 86 | 0.260 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2021 | 1373 | 0.250 |
Why?
|
| Alanine Transaminase | 2 | 2016 | 162 | 0.250 |
Why?
|
| Biopsy | 2 | 2020 | 1299 | 0.250 |
Why?
|
| Prospective Studies | 3 | 2022 | 6561 | 0.250 |
Why?
|
| Fibrosis | 3 | 2022 | 460 | 0.220 |
Why?
|
| Reproducibility of Results | 3 | 2025 | 3045 | 0.220 |
Why?
|
| Aged | 8 | 2025 | 21397 | 0.210 |
Why?
|
| Fast Foods | 1 | 2023 | 35 | 0.210 |
Why?
|
| Odds Ratio | 2 | 2016 | 1333 | 0.210 |
Why?
|
| Physicians, Primary Care | 1 | 2024 | 96 | 0.200 |
Why?
|
| Young Adult | 4 | 2018 | 9728 | 0.190 |
Why?
|
| Cluster Analysis | 1 | 2023 | 438 | 0.190 |
Why?
|
| Safety-net Providers | 2 | 2020 | 61 | 0.190 |
Why?
|
| Disease Management | 2 | 2018 | 553 | 0.190 |
Why?
|
| Hypertension, Portal | 2 | 2021 | 81 | 0.190 |
Why?
|
| Public Health | 1 | 2023 | 286 | 0.180 |
Why?
|
| Observer Variation | 2 | 2025 | 313 | 0.180 |
Why?
|
| Proof of Concept Study | 1 | 2021 | 31 | 0.180 |
Why?
|
| Actigraphy | 1 | 2021 | 47 | 0.170 |
Why?
|
| Primary Health Care | 2 | 2024 | 790 | 0.170 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 3932 | 0.170 |
Why?
|
| Incidence | 2 | 2018 | 3349 | 0.160 |
Why?
|
| Education, Medical, Graduate | 1 | 2024 | 552 | 0.160 |
Why?
|
| Multicenter Studies as Topic | 1 | 2020 | 287 | 0.160 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2019 | 41 | 0.150 |
Why?
|
| Health Behavior | 1 | 2022 | 400 | 0.150 |
Why?
|
| Linear Models | 1 | 2021 | 724 | 0.150 |
Why?
|
| Rooming-in Care | 1 | 2018 | 1 | 0.150 |
Why?
|
| Safety | 1 | 2019 | 223 | 0.150 |
Why?
|
| Urban Health | 1 | 2018 | 78 | 0.140 |
Why?
|
| Hepatic Encephalopathy | 1 | 2019 | 88 | 0.140 |
Why?
|
| Risk | 1 | 2020 | 832 | 0.140 |
Why?
|
| Emigration and Immigration | 1 | 2018 | 82 | 0.140 |
Why?
|
| Communicable Diseases | 1 | 2020 | 163 | 0.140 |
Why?
|
| Bile Ducts, Extrahepatic | 1 | 2017 | 14 | 0.140 |
Why?
|
| End Stage Liver Disease | 1 | 2020 | 198 | 0.140 |
Why?
|
| Latin America | 1 | 2017 | 98 | 0.140 |
Why?
|
| Ultrasonography | 2 | 2025 | 973 | 0.140 |
Why?
|
| Asia | 1 | 2017 | 127 | 0.140 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 199 | 0.140 |
Why?
|
| Electronic Health Records | 1 | 2024 | 781 | 0.130 |
Why?
|
| Age Distribution | 1 | 2018 | 442 | 0.130 |
Why?
|
| Cooperative Behavior | 1 | 2018 | 229 | 0.130 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 7133 | 0.130 |
Why?
|
| Work Schedule Tolerance | 1 | 2016 | 42 | 0.130 |
Why?
|
| Food Supply | 1 | 2017 | 101 | 0.130 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2017 | 106 | 0.130 |
Why?
|
| Emigrants and Immigrants | 1 | 2018 | 148 | 0.120 |
Why?
|
| Retrospective Studies | 5 | 2022 | 17174 | 0.120 |
Why?
|
| Self Report | 1 | 2019 | 545 | 0.120 |
Why?
|
| Patient Education as Topic | 1 | 2019 | 458 | 0.120 |
Why?
|
| Dyslipidemias | 1 | 2018 | 243 | 0.120 |
Why?
|
| Hepatopulmonary Syndrome | 1 | 2014 | 8 | 0.110 |
Why?
|
| Hydrothorax | 1 | 2014 | 11 | 0.110 |
Why?
|
| Length of Stay | 1 | 2020 | 1355 | 0.110 |
Why?
|
| Antiviral Agents | 1 | 2019 | 811 | 0.110 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2022 | 993 | 0.110 |
Why?
|
| Disease Progression | 1 | 2019 | 2208 | 0.100 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 1484 | 0.100 |
Why?
|
| Risk Assessment | 2 | 2024 | 3621 | 0.100 |
Why?
|
| Quality Improvement | 1 | 2018 | 682 | 0.100 |
Why?
|
| Liver Neoplasms | 1 | 2022 | 1402 | 0.090 |
Why?
|
| Logistic Models | 1 | 2016 | 1896 | 0.090 |
Why?
|
| Inflammation | 1 | 2019 | 1584 | 0.090 |
Why?
|
| Registries | 1 | 2018 | 1528 | 0.090 |
Why?
|
| Diarrhea | 1 | 2012 | 339 | 0.090 |
Why?
|
| Hospitalization | 1 | 2019 | 1840 | 0.080 |
Why?
|
| Age Factors | 1 | 2016 | 2960 | 0.080 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2012 | 222 | 0.080 |
Why?
|
| Texas | 1 | 2018 | 3647 | 0.080 |
Why?
|
| Clostridium Infections | 1 | 2012 | 250 | 0.080 |
Why?
|
| Hypertension, Pulmonary | 1 | 2014 | 458 | 0.080 |
Why?
|
| Quality of Life | 1 | 2019 | 2098 | 0.080 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2012 | 322 | 0.070 |
Why?
|
| Cardiovascular Diseases | 1 | 2021 | 2043 | 0.070 |
Why?
|
| Case-Control Studies | 1 | 2015 | 3605 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 1148 | 0.070 |
Why?
|
| Time Factors | 1 | 2018 | 6519 | 0.070 |
Why?
|
| Prognosis | 1 | 2017 | 5029 | 0.070 |
Why?
|
| Chile | 1 | 2025 | 25 | 0.060 |
Why?
|
| Infant, Newborn | 1 | 2018 | 8490 | 0.060 |
Why?
|
| Longitudinal Studies | 1 | 2025 | 1460 | 0.040 |
Why?
|
| Physical Fitness | 1 | 2021 | 94 | 0.040 |
Why?
|
| Menopause | 1 | 2021 | 83 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2024 | 605 | 0.040 |
Why?
|
| Risk Reduction Behavior | 1 | 2021 | 148 | 0.040 |
Why?
|
| Hospitals, Urban | 1 | 2020 | 99 | 0.040 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2020 | 144 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2024 | 2280 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2024 | 1694 | 0.040 |
Why?
|
| Metabolic Syndrome | 1 | 2021 | 365 | 0.030 |
Why?
|
| Adolescent | 1 | 2015 | 20225 | 0.030 |
Why?
|
| Cross Infection | 1 | 2020 | 329 | 0.030 |
Why?
|
| Hospitals | 1 | 2019 | 421 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2019 | 401 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2020 | 1056 | 0.030 |
Why?
|
| Child | 1 | 2015 | 25423 | 0.030 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2014 | 21 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 1599 | 0.030 |
Why?
|
| Diuretics | 1 | 2014 | 169 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2020 | 5166 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2014 | 1237 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 2502 | 0.020 |
Why?
|
| Liver Transplantation | 1 | 2014 | 1099 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2020 | 12861 | 0.010 |
Why?
|